RxDoctor Payments Data

Kanat Ransibrahmanakul, MD

Internal Medicine · Folsom, CANPI 1407831662

Payments from drug & device makers

$17,118in general payments, 2019–2025

Across 802 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Sanofi$870
  • Pfizer$374
  • plus $4K from 27 others

What the payments were for

  • Speaking & faculty fees$1,75010%
  • Food & beverage$15,15189%
  • Education$2161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,118 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$238,277
Medicare patients
465
Services billed
2,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase34$133,517
LinzessLinaclotide39$46,963
XifaxanRifaximin17$46,282
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates199$13,535
CholestyramineCholestyramine (With Sugar)51$6,835
Budesonide EcBudesonide15$4,292
Mesalamine22$3,145
Omeprazole157$2,858
Pantoprazole Sodium163$2,333
Budesonide DrBudesonide13$2,282
Sucralfate30$1,985
Famotidine70$1,084
Ursodiol16$677
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg29$580
Spironolactone16$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$6,783$180,48173 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,037$46,28217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →